{"filing":{"accession_number":"0001437749-26-030392","cik":"0001625101","ticker":"PLSE","company_name":"PULSE BIOSCIENCES, INC.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-15","primary_document":"plse20260827_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926030392/plse20260827_8k.htm"},"events":[{"id":33519,"run_id":30821,"accession_number":"0001437749-26-030392","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Pulse Biosciences announced completion of patient enrollment in its PRECISE-BTN clinical study for the nPulse™ Vybrance™ system, with enrollment expanded from 50 to 100 patients and the first patient completing 12-month follow-up. This is a material clinical development milestone for a medical device company, representing progress toward regulatory approval and commercialization, but does not fit the specific event categories (earnings, M\u0026A, impairment, litigation, etc.). It is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's product development trajectory.","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":36980,"accession_number":"0001437749-26-030392","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Pulse Biosciences announced completion of patient enrollment in its PRECISE-BTN clinical study for the nPulse™ Vybrance™ system, with enrollment expanded from 50 to 100 patients and the first patient completing 12-month follow-up. This is a material clinical development milestone for a medical device company, representing progress toward regulatory approval and commercialization, but does not fit the specific event categories (earnings, M\u0026A, impairment, litigation, etc.). It is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's product development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:56:08.356947+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36980,"accession_number":"0001437749-26-030392","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Pulse Biosciences announced completion of patient enrollment in its PRECISE-BTN clinical study for the nPulse™ Vybrance™ system, with enrollment expanded from 50 to 100 patients and the first patient completing 12-month follow-up. This is a material clinical development milestone for a medical device company, representing progress toward regulatory approval and commercialization, but does not fit the specific event categories (earnings, M\u0026A, impairment, litigation, etc.). It is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's product development trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T12:56:08.356947+00:00","company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","filing_date":"2026-09-15"}]}